期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细胞质胸苷激酶1对食管癌诊断和复发评估的价值

下载PDF
导出
摘要 目的探讨食管癌患者血清细胞质胸苷激酶1（TK1）的水平在食管癌的诊断和复发评估中的作用。方法收集34例食管癌患者术前、术后1周和术后1月的血清，同时选取41例健康体检者作为对照。检测各组TK1水平并观察其动态变化，分析TK1变化趋势与食管癌患者无复发生存率（RFS）的相关性。结果34例食管癌患者的TK1平均浓度为4．839±0．421pM，显著高于健康对照组1．068±0．136pM（P〈0．01），术后1月TK1水平较术前显著下降（2．248±0．200pM）（P〈0．01），且术后1月TK1水平评估为PR组的患者无复发生存率（啪）显著高于SD＋PD组（P〈0．05）。结论血清TK1作为一种新的肿瘤标志物，在食管癌的诊断和复发评估中有着潜在的应用价值。
作者 韩卫卫 朱明
机构地区 苏州大学附属常州市肿瘤医院胸外科 苏州大学附属常州市肿瘤医院肿瘤实验室
出处 《常州实用医学》 2014年第5期302-304,共3页 CHANGZHOU PRACTICAL MEDICINE
关键词 TK1 食管癌 诊断 无复发生存率
分类号 R446.1 [医药卫生—诊断学]
  • 相关文献

参考文献8

  • 1XIANG Y, ZENG H,LIU X, et al. Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in Cancer pa- tients: A meta - analysis[ J]. Biomed REP, 2013, 1 (4) : 629 - 637.
  • 2ALEGRE M M,WEYANT M J,BENNE3"T D T,et al. Serumdetection of thymidine kinase 1 as a means of early detection of lung Cancer [J]. Anticanecr RES, 2014, 3 (45) : 2145 - 2151.
  • 3王振欣,章斌,倪斌,藏晋.血清胸苷激酶1在恶性肿瘤疗效评估中的价值[J].江苏医药,2011,37(18):2174-2176. 被引量：5
  • 4BROCKENBROUGH J, RASEY J S, GRIERSON J R, et al. A simple quantitative assay for the activity of thymidine kinase 1 in solid tumors[J]. NUCL MED BIOL, 2007,34(6):619- 623.
  • 5LI Z, WANG Y, MA J, et 81. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with careinoma[J]. Antieaneer Research,2010,30(4) : 1295 - 1299.
  • 6ZOU L, ZHANG P - g, ZOU S, et al. The half- life of thymi-dine kinase 1 in serum measured by ECL dot blot:a potential marker for monitoring the response to surgery of patients with gastric Cancer[J]. INT J BIOL Markers,2002,17(2) : 135 - 140.
  • 7HE E, XU X- h,GUAN H,et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal Cancer and non-Hodgkin's lymphoma[J]. Nucleosides Nucleotldes Nucleic Acids. ,2010,29(4/6) :352 - 358.
  • 8KORKMAZ T,SEBER S,OKUTUR K,et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung Cancer[J] . Biomarkers, 2013,18(1) :88 - 94.

二级参考文献6

  • 1He Q,Fornander T,Johansson H,et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer [J]. Anticancer Res, 2006,26(6C) : 4753-4759.
  • 2Xu XH,Zhang YM,Shu XH,et al. Serum thyrnidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy[J]. Mol Med Report, 2008,1 (5) : 705-711.
  • 3Topolcan O, Holubec L. The role of thyrnidine kinase in cancer diseases[J]. Expert Opin Med Diagn, 2008,2 (2) : 129-141.
  • 4Li HX,Lei DS,Wang XQ,et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer[J]. Oncol Rep, 2005,13(1) : 145-149.
  • 5Zhang J ,Jia Q, Zou S, et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients[J]. Oncol Rep, 2006,15(2) : 455-461.
  • 6He Q, Zhang P, Zou L, et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity[J]. Oncol Rep, 2005, 14 (4):1013-1019.

共引文献4

常州实用医学
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部